114 related articles for article (PubMed ID: 24495689)
1. [Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats].
Gao H; Xi S; Xu L
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):935-8. PubMed ID: 24495689
[TBL] [Abstract][Full Text] [Related]
2. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
[TBL] [Abstract][Full Text] [Related]
4. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
5. The effects of conjugated estrogen, raloxifene and soy extract on collagen in rat bones.
Condi FL; Soares JM; Teodoro WR; Veloso AP; Parra ER; de Jesus Simoes M; Baracat EC
Climacteric; 2012 Oct; 15(5):441-8. PubMed ID: 22208761
[TBL] [Abstract][Full Text] [Related]
6. Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats.
Hascalik S; Celik O; Tamser M; Mizrak B
Gynecol Obstet Invest; 2005; 60(4):186-91. PubMed ID: 16020933
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
8. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
9. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy.
Nozaki M; Ogata R; Koera K; Hashimoto K; Nakano H
Climacteric; 1999 Jun; 2(2):124-30. PubMed ID: 11910665
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance spectroscopic comparison of the effects of resveratrol (3,4',5-trihydroxy stilbene) to conjugated equine estrogen, tibolone and raloxifene on ovariectomized rat brains.
Celik O; Erdem G; Hascalik S; Karakas HM; Tamser M
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):73-9. PubMed ID: 15866090
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells.
Okano H; Jayachandran M; Yoshikawa A; Miller VM
J Cardiovasc Pharmacol; 2006 Apr; 47(4):621-8. PubMed ID: 16680078
[TBL] [Abstract][Full Text] [Related]
12. Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus.
Sztejnsznajd C; Silva ME; Nussbacher A; Gebara OE; D'Amico EA; Rocha DM; da Rocha TR; Santos RF; Wajngarten M; Fukui RT; Correia MR; Wajchenberg BL; Ursich MJ
Metabolism; 2006 Jul; 55(7):953-9. PubMed ID: 16784970
[TBL] [Abstract][Full Text] [Related]
13. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
14. Effects of raloxifene treatment on the phenotype of blood monocytes.
Boudjeltia KZ; Durez P; Oberweis D; Guillaume M; Remacle C; Cauchie P; Vanhaeverbeek M; Brohée D; Ducobu J; Gregoir C
Can J Physiol Pharmacol; 2010 May; 88(5):601-5. PubMed ID: 20555430
[TBL] [Abstract][Full Text] [Related]
15. [Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women].
Carranza Lira S; MacGregor Gooch AL; Olivares A; González Legorreta SL; Saldívar N; Martínez Chéquer JC
Ginecol Obstet Mex; 2005 Oct; 73(10):521-4. PubMed ID: 16583831
[TBL] [Abstract][Full Text] [Related]
16. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
Tsai KS; Yen ML; Pan HA; Wu MH; Cheng WC; Hsu SH; Yen BL; Huang KE
Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
[TBL] [Abstract][Full Text] [Related]
18. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
19. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
[TBL] [Abstract][Full Text] [Related]
20. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis.
Ando H; Otoda T; Ookami H; Nagai Y; Inano A; Takamura T; Ushijima K; Hosohata K; Matsushita E; Saito T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):227-32. PubMed ID: 23323567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
